Generic Natesto Availability
Last updated on Apr 10, 2024.
Natesto is a brand name of testosterone, approved by the FDA in the following formulation(s):
NATESTO (testosterone - gel, metered;nasal)
-
Manufacturer: ACERUS
Approval date: May 28, 2014
Strength(s): 5.5MG/0.122GM ACTUATION [RLD]
Has a generic version of Natesto been approved?
No. There is currently no therapeutically equivalent version of Natesto available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Natesto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,090,312
Patent expiration dates:
- March 17, 2034✓
- March 17, 2034
-
Controlled release delivery system for nasal applications
Patent 8,574,622
Issued: November 5, 2013
Inventor(s): Mattern Claudia
Assignee(s): M & P Patent AktiengesellschaftThis invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.
Patent expiration dates:
- February 4, 2024✓
- February 4, 2024
-
Controlled release delivery system for nasal applications and methods of treatment
Patent 8,784,869
Issued: July 22, 2014
Inventor(s): Mattern Claudia
Assignee(s): Mattern Pharma AGThis invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Patent expiration dates:
- February 4, 2024✓
- February 4, 2024
-
Controlled release delivery system for nasal applications and method of treatment
Patent 8,784,882
Issued: July 22, 2014
Inventor(s): Mattern Claudia
Assignee(s): Mattern Pharma AGThis invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
Patent expiration dates:
- February 4, 2024✓✓
- February 4, 2024
-
Controlled release delivery system for nasal applications
Patent 8,877,230
Issued: November 4, 2014
Inventor(s): Mattern Claudia
Assignee(s): Mattern Pharma AGThis invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action.
Patent expiration dates:
- February 4, 2024✓
- February 4, 2024
More about Natesto (testosterone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (5)
- Latest FDA alerts (7)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: androgens and anabolic steroids
- Breastfeeding
- En español
Patient resources
Other brands
AndroGel, Depo-Testosterone, Xyosted, Testim, ... +13 more
Professional resources
Other brands
AndroGel, Depo-Testosterone, Xyosted, Androderm, ... +10 more
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.